达格列净联合用药治疗糖尿病的临床研究进展  

Recent advances in clinical research of dapagliflozin plus other hypoglycemic agents in the treatment of diabetes

作　　者：杜婉笛 杨晓蕾 刘玉萍 刘烨 杨庆 管瑞芳 胡嘉容 马国[1] DU Wan-di;YANG Xiao-lei;LIU Yu-ping;LIU Ye;YANG Qing;GUAN Rui-fang;HU Jia-rong;MA Guo(School of Pharmacy,Fudan University,Shanghai 201203,China)

机构地区：[1]复旦大学药学院,上海201203

出　　处：《中国医院药学杂志》2021年第19期2026-2030,共5页Chinese Journal of Hospital Pharmacy

基　　金：国家自然科学基金面上项目(编号:82074109,81873078,81374051);上海市卫生和计划生育委员会科研课题(编号:201740094);中医药科研课题(编号:2018YP001);复旦大学附属闵行医院-复旦大学药学院青年人才项目(编号:2021MHJC11)。

摘　　要：糖尿病是一种以高血糖为特征的慢性代谢性疾病,给人类生命健康带来严重危害。当单一降糖药疗效不佳时,常采用2种及2种以上降糖药进行治疗。达格列净是近年新上市的一种钠-葡萄糖共转运蛋白2(sodium-glucose contransporter 2,SGLT2)抑制剂,用于糖尿病疗效显著,不良反应少,应用广泛。临床上糖尿病及其并发症治疗效果不佳时,常将达格列净与胰岛素、二甲双胍、利拉鲁肽、沙格列汀、吡格列酮、阿卡波糖、中药等联用,以增强疗效,降低不良反应发生率。本文通过对达格列净与上述降糖药物联用治疗糖尿病的疗效和安全性进行总结和评价,以期为SGLT2抑制剂联合用药、降糖药合理应用和糖尿病治疗提供参考。As a chronic metabolic disease characterized by hyperglycemia, diabetes mellitus brings serious harm to human life and health. When a single hypoglycemic agent shows a poor efficacy, two or more drug combinations are often used. As a sodium-glucose cotransporter 2 inhibitor newly marketed, dapagliflozin has been widely applied due to its marked efficacy and few adverse reactions. It is often used in combination with insulin, metformin, liraglutide, saxagliptin, pioglitazone, acarbose and traditional Chinese medicine to treat diabetes and diabetic complications. Therefore the efficacy and safety of dapagliflozin plus other hypoglycemic agents in the treatment of diabetes are summarized for providing references for combined uses of SGLT2 inhibitors, rational uses of hypoglycemic agents and a proper treatment of diabetes mellitus.

关 键 词：达格列净 钠-葡萄糖共转运蛋白2抑制剂 糖尿病 联合用药 有效性 安全性 

分 类 号：R969.3[医药卫生—药理学]